Revisiting the druggable genome using predicted structures and data mining.

  • Journal Article

Journal:
NPJ drug discovery, Volume: 2, Issue: 1
Published:
March 4, 2025
PMID:
40066064
Authors:
Karla P Godinez-Macias KP, Daisy Chen D, J Lincoln Wallis JL, Miles G Siegel MG, Anna Adam A, Selina Bopp S, Krypton Carolino K, Lauren B Coulson LB, Greg Durst G, Vandana Thathy V, Lisl Esherick L, Madeline A Farringer MA, Erika L Flannery EL, Barbara Forte B, Tiqing Liu T, Luma Godoy Magalhaes L, Anil K Gupta AK, Eva S Istvan ES, Tiantian Jiang T, Krittikorn Kumpornsin K, Karen Lobb K, Kyle J McLean KJ, Igor M R Moura IMR, John Okombo J, N Connor Payne NC, Andrew Plater A, Srinivasa P S Rao SPS, Jair L Siqueira-Neto JL, Bente A Somsen BA, Robert L Summers RL, Rumin Zhang R, Michael K Gilson MK, Francisco-Javier Gamo FJ, Brice Campo B, Beatriz BaragaƱa B, James Duffy J, Ian H Gilbert IH, Amanda K Lukens AK, Koen J Dechering KJ, Jacquin C Niles JC, Case W McNamara CW, Xiu Cheng X, Lyn-Marie Birkholtz LM, Alfred W Bronkhorst AW, David A Fidock DA, Dyann F Wirth DF, Daniel E Goldberg DE, Marcus C S Lee MCS, Elizabeth A Winzeler EA
Abstract:

Identification of novel drug targets is a key component of modern drug discovery. While antimalarial targets are often identified through the mechanism of action studies on phenotypically derived inhibitors, this method tends to be time- and resource-consuming. The discoverable target space is also constrained by existing compound libraries and phenotypic assay conditions. Leveraging recent advances in protein structure prediction, we systematically assessed the genome and identified 867 candidate protein targets with evidence of small-molecule binding and blood-stage essentiality. Of these, 540 proteins showed strong essentiality evidence and lack inhibitors that have progressed to clinical trials. Expert review and rubric-based scoring of this subset based on additional criteria such as selectivity, structural information, and assay developability yielded 27 high-priority antimalarial target candidates. This study also provides a genome-wide data resource for and implements a generalizable framework for systematically evaluating and prioritizing novel pathogenic disease targets.


Courtesy of the U.S. National Library of Medicine